Aptiv Cuts FY Sales Outlook

Aptiv Plc. (APTV) now expects full year 2021 sales to be in the range of $15.1 billion to $15.5 billion, down 6% at the midpoint versus a previous range of $16.1 billion to $16.4 billion.

Full year 2021 adjusted operating income margins are now expected to be in the range of 7.6% to 8.4% versus a previous range of 9.9% to 10.2%, which includes the impacts of operating inefficiencies, increased supply chain disruption costs and other uncertainties.

The updated outlook reflects a 7% decrease in global vehicle production rates, from 85 million to 79 million units, at the time the previous full year 2021 guidance was issued on August 5, 2021.

Although the company still expects revenue growth over market to be consistent with the previously issued financial guidance of 10% for 2021, global vehicle production for the third quarter is currently expected to be approximately 18 million units, or a decrease of approximately 15% from the 21 million units expected at the time the previous full year guidance was issued.

Global vehicle production for the fourth quarter is currently expected to be approximately 20 million units, or a decrease of approximately 13% from the 23 million units expected previously.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin. Twitter Inc. said it is expanding engineering center in Singapore, its Asia Pacific headquarters. The number of engineers there will be doubled to over 100 staff in 2023. Focused on product innovations and improvements, the new hires will work from Singapore on global initiatives for Twitter. These new technical hires will span roles in engineering, data science, machine learning and product... The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease.
Follow RTT